Eric Rowinsky

Eric K. Rowinsky, MD brings over 30 years of extensive oncology and corporate strategy expertise, research and drug development experience, and broad scientific and medical knowledge to the Radyus Research Advisory Board.

Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs, an Editorial Board Member of Cancer Research and several other oncology journals and has published approximately 315 manuscripts in both the nonclinical and clinical research fields. He has also served on the Board of Directors, Scientific Advisory Board and Project Advisory Boards of many pharmaceutical and biotechnology companies, as well investor groups, and has advised and/or presented aspects of NDAs to the FDA on many occasions. Since 2015, Dr. Rowinsky has served as an Executive Director and President at Rgenix Inc., a life sciences company focused on discovering new cancer targets using a novel microRNA platform, as well as the Chief Scientific Officer of ClearPath Development Co., which rapidly advances development stage therapeutic assets to pre-defined human Proof-of-Concept milestones. Dr. Rowinsky served as the Director of Clinical Research and later Director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio where he held the SBC Endowed Chair for Early Drug Development and was a lead investigator on early developmental studies of many classes of targeted therapeutics such as erlotinib, gefitinib, panitumumab, temsirolimus, ridaforolimus, trabectedin, and many other agents. Dr. Rowinsky served as an Associate Professor of Oncology at the Johns Hopkins University School of Medicine where he performed seminal clinical development and pharmacologic studies on paclitaxel, docetaxel, irinotecan, topotecan, among other agents, some of which led to the registration of these products in various indications. Dr. Rowinsky received his BA degree from New York University and his MD from the Vanderbilt University School of Medicine. Following his residency in internal medicine at the University of California, he completed fellowship training in medical oncology and clinical pharmacology at the Johns Hopkins University School of Medicine.